#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10308	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2225	452.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1532	1532	C	692	C,T	592,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	10308	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2225	452.0	0	HET	.	.	.	C388T	.	388	388	C	736	736	C	535	C,T	321,145	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18784	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3456	529.6	0	.	n	.	0	T695C	SNP	695	695	T	986	986	C	735	C	660	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18784	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3456	529.6	0	.	n	.	0	G1337A	SNP	1337	1337	G	1628	1628	A	481	A	457	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18784	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3456	529.6	0	.	n	.	0	T1971C	SNP	1971	1971	T	2262	2262	C	601	C	506	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18784	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3456	529.6	1	SNP	n	A2045G	1	A2045G	SNP	2045	2045	A	2336	2336	G	629	G	547	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	18784	23S	2890	2890	99.86	23S.l15.c30.ctg.1	3456	529.6	1	SNP	n	C2597T	0	.	.	2597	2597	C	2888	2888	C	580	C	504	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
blaTEM.WHO_M_pConjugative_00003	blaTEM.WHO_M_pConjugative_00003	1	0	539	30814	blaTEM	861	861	99.88	blaTEM.l15.c30.ctg.1	1405	2143.6	0	.	p	.	0	M180T	NONSYN	538	540	ATG	785	787	ACG	3059;3070;3074	A,C;C;G,A	2547,1;2572;2567,1	.	Betalactam resistance
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	754	folP	855	855	99.88	folP.l6.c30.ctg.1	1775	41.2	1	SNP	p	R229S	1	.	.	685	687	AGC	1135	1137	AGC	101;101;104	A;G;C	84;84;86	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	2172	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3424	61.2	0	.	p	.	0	D95A	NONSYN	283	285	GAC	729	731	GCC	94;93;93	G;C;C	88;85;86	.	.
gyrA.WHO_G_01105	gyrA.WHO_G_01105	1	1	539	2172	gyrA	2751	2751	99.96	gyrA.l15.c4.ctg.1	3424	61.2	1	SNP	p	S91F	1	.	.	271	273	TTC	717	719	TTC	89;89;88	T;T;C	83;82;81	gyrA.WHO_G_01105:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
mtrR.WHO_M_01390	mtrR.WHO_M_01390	1	1	27	522	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1325	38.2	1	SNP	p	G45D	1	.	.	133	135	GAC	496	498	GAC	80;80;80	G;A;C	73;73;74	mtrR.WHO_M_01390:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	400	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	891	42.5	0	.	n	.	0	A197.	DEL	197	197	A	478	478	A	102	A	91	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1790	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2932	59.0	1	SNP	p	D86N	0	.	.	256	258	GAC	514	516	GAC	75;76;76	G;A;C	71;68;70	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1790	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2932	59.0	1	SNP	p	R87W	0	.	.	259	261	CGT	517	519	CGT	74;74;74	C;G;T	69;69;68	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1790	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2932	59.0	1	SNP	p	R87I	0	.	.	259	261	CGT	517	519	CGT	74;74;74	C;G;T	69;69;68	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1790	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2932	59.0	1	SNP	p	S87R	1	.	.	259	261	CGT	517	519	CGT	74;74;74	C;G;T	69;69;68	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	1790	parC	2304	2304	99.91	parC.l15.c4.ctg.1	2932	59.0	1	SNP	p	S88P	0	.	.	262	264	TCC	520	522	TCC	74;74;72	T;C;C	69;69;67	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1556	parE	1986	1986	99.85	parE.l15.c4.ctg.1	2750	54.3	0	.	p	.	0	V324_Q325insL	INS	970	970	G	1261	1261	G	81	G	73	.	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	539	1556	parE	1986	1986	99.85	parE.l15.c4.ctg.1	2750	54.3	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1522	1524	GGC	44;44;44	G;G;C	42;42;42	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	A311V	0	.	.	931	933	GCA	1184	1186	GCA	124;123;126	G;C;A	107;107;108	penA.2.002:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	I312M	0	.	.	934	936	ATC	1187	1189	ATC	127;127;127	A;T;C	112;112;112	penA.2.002:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	V316P	0	.	.	946	948	GTG	1199	1201	GTG	120;121;118	G;T;G	106;106;105	penA.2.002:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	V316T	0	.	.	946	948	GTG	1199	1201	GTG	120;121;118	G;T;G	106;106;105	penA.2.002:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1703	1705	ACC	77;74;70	A;C;C	72;72;68	penA.2.002:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1757	1759	GCG	54;54;54	G;C;G	50;51;50	penA.2.002:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1757	1759	GCG	54;54;54	G;C;G	50;51;50	penA.2.002:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1880	1882	GGC	32;32;32	G;G;C	32;32;32	penA.2.002:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1889	1891	GGC	24;24;25	G;G;C	24;24;25	penA.2.002:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.002	penA.2.002	1	1	27	1840	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2311	76.9	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1907	1909	CCG	17;14;14	C;C;G	17;14;14	penA.2.002:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	3420	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3001	110.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1490	1492	CCG	52;52;53	C;C;G	47;47;45	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	513	814	porA	1146	838	99.64	porA.l15.c30.ctg.1	986	61.5	0	.	p	.	0	D129G	NONSYN	385	387	GAC	77	79	GGC	34;34;32	G;G;C	30;30;29	.	.
porA.NCCP11945	porA.NCCP11945	1	0	513	814	porA	1146	838	99.64	porA.l15.c30.ctg.1	986	61.5	0	.	p	.	0	G271E	NONSYN	811	813	GGG	503	505	GAG	69;67;67	G;A;G	61;60;60	.	.
porA.NCCP11945	porA.NCCP11945	1	0	513	814	porA	1146	838	99.64	porA.l15.c30.ctg.1	986	61.5	0	.	p	.	0	G273fs	FSHIFT	817	817	G	508	508	A	59	A	52	.	.
porA.NCCP11945	porA.NCCP11945	1	0	513	814	porA	1146	337	99.41	porA.l15.c30.ctg.2	410	36.8	0	.	p	.	0	S22G	NONSYN	64	66	AGC	138	140	GGC	53;53;54	G;G;C	46;45;46	.	.
porA.NCCP11945	porA.NCCP11945	1	0	513	814	porA	1146	337	99.41	porA.l15.c30.ctg.2	410	36.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	320	320	C	28	C	25	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	H217N	NONSYN	649	651	CAT	205	207	AAT	9;9;9	A;A;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	D218N	NONSYN	652	654	GAT	208	210	AAT	9;9;9	A;A;T	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	A222V	NONSYN	664	666	GCT	220	222	GTT	10;10;11	G;T;T	10;10;11	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	V226A	NONSYN	676	678	GTA	232	234	GCG	10;10;10	G;C;G	10;10;10	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	.	MULTIPLE	700	702	ACT	255	257	GTA	6;6;6	G;T;A	6;5;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	N237K	NONSYN	709	711	AAC	264	266	AAG	9;9;9	A;A;G	9;9;9	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	92	porB1a	984	188	90.1	porB1a.l15.c17.ctg.1	375	8.5	0	.	p	.	0	D238fs	FSHIFT	712	712	G	267	267	G	9	G	9	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1130	porB1b	1047	1047	99.52	porB1b.l6.c4.ctg.1	1714	64.8	0	.	p	.	0	A26T	NONSYN	76	78	GCC	471	473	ACC	99;100;93	A;C;C	89;91;84	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1130	porB1b	1047	1047	99.52	porB1b.l6.c4.ctg.1	1714	64.8	1	SNP	p	G120K	1	G120K	NONSYN	358	360	GGC	753	755	AAG	75;74;74	A;A;G	68;67;67	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1130	porB1b	1047	1047	99.52	porB1b.l6.c4.ctg.1	1714	64.8	1	SNP	p	A121D	1	.	.	361	363	GAC	756	758	GAC	74;69;67	G;A;C	67;62;61	porB1b.WHO_P_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	1130	porB1b	1047	1047	99.52	porB1b.l6.c4.ctg.1	1714	64.8	1	SNP	p	D121N	0	.	.	361	363	GAC	756	758	GAC	74;69;67	G;A;C	67;62;61	porB1b.WHO_P_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	98	porB3	990	116	92.24	porB3.l6.c4.ctg.1	288	11.0	0	.	p	.	0	M18T	NONSYN	52	54	ATG	161	163	ACG	21;20;19	A;C;G	16;15;14	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	98	porB3	990	116	92.24	porB3.l6.c4.ctg.1	288	11.0	0	.	p	.	0	T29A	NONSYN	85	87	ACC	194	196	GCC	12;12;12	G;C;C	9;9;9	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	98	porB3	990	116	92.24	porB3.l6.c4.ctg.1	288	11.0	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	203	205	CAA	6;5;4	C;A;A	5;4;4	.	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	98	porB3	990	116	92.24	porB3.l6.c4.ctg.1	288	11.0	0	.	p	.	0	S34Y	NONSYN	100	102	TCC	209	211	TAC	3;3;3	T;A;C	3;3;3	.	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	539	4082	rpoB	4179	4179	99.95	rpoB.l15.c4.ctg.1	4863	82.0	0	.	p	.	0	L560F	NONSYN	1678	1680	TTG	1805	1807	TTT	115;113;113	T;T;T	100;98;98	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	308	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1062	28.3	1	SNP	p	V57M	1	.	.	169	171	ATG	599	601	ATG	44;42;46	A;T;G	41;39;43	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	13232	tetM	1920	1920	100.0	tetM.l15.c30.ctg.1	2392	545.4	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
